Pharmacotherapy for oesophagogastric cancer.

Abstract:

:Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. Despite improvements in surgical and peri-operative supportive care, 3-year overall survival with surgery alone for resectable disease is still poor. Outcomes in localised oesophageal cancer are improved with pre-operative chemotherapy, and in gastric cancer with peri-operative treatment or post-operative chemoradiotherapy. Oesophageal squamous cell carcinoma can be treated with definitive chemoradiotherapy as an alternative to surgery. While survival in patients presenting with metastatic disease is improved with the addition of systemic chemotherapy, median survival remains <1 year. Patients who are otherwise fit can be offered chemotherapy and this is superior to best supportive care. Regimens including a platinum and an anthracycline agent are favoured by the results of randomised trials. No standard second-line therapy has emerged. New research into taxanes has shown promising anti-cancer activity, and novel areas of investigation include incorporation of agents targeting vascular endothelial growth factor or epidermal growth factor receptor into standard regimens. This review focuses on the clinical trial evidence that dictates the optimal management of localised and advanced oesophagogastric cancer, focusing on pharmacotherapy. We examine areas of current research and highlight future therapeutic directions.

journal_name

Drugs

journal_title

Drugs

authors

Jackson C,Starling N,Chua YJ,Cunningham D

doi

10.2165/00003495-200767170-00006

subject

Has Abstract

pub_date

2007-01-01 00:00:00

pages

2539-56

issue

17

eissn

0012-6667

issn

1179-1950

pii

67176

journal_volume

67

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Drotrecogin alfa (activated).

    abstract::Drotrecogin alfa (activated), recombinant human activated protein C, inhibits coagulation and inflammation and promotes fibrinolysis in patients with severe sepsis. 850 patients with severe sepsis treated with intravenous drotrecogin alfa (activated) 24 microg/kg/h for 96 hours had a significantly greater reduction in...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-200262040-00006

    authors: Lyseng-Williamson KA,Perry CM

    更新日期:2002-01-01 00:00:00

  • Concentration of sulbactam and ampicillin in serum and the myometrium.

    abstract::Sulbactam 1g and ampicillin 2g were administered intravenously to 12 patients, and concentrations of the drugs were determined in the serum and myometrium for up to 120 minutes after infusion. The ratio of sulbactam to ampicillin was about 1:2 in the serum and myometrium. Both drugs penetrated well into the myometrium...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600312-00007

    authors: Schwiersch U,Lang N,Wildfeuer DA

    更新日期:1986-01-01 00:00:00

  • Management of chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is characterised by insidiously progressive airflow limitation. The necessarily multifactorial management programme should include smoking cessation, prevention of infections, bronchodilator and steroid therapy, supplemental oxygen, physical therapy, pulmonary rehabilitatio...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198938010-00007

    authors: Kesten S,Rebuck AS

    更新日期:1989-07-01 00:00:00

  • Anagrelide: a review of its use in the management of essential thrombocythaemia.

    abstract::Anagrelide (Agrylin, Xagrid) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of elevated platelet counts and t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666010-00006

    authors: Wagstaff AJ,Keating GM

    更新日期:2006-01-01 00:00:00

  • Tipranavir: a ritonavir-boosted protease inhibitor.

    abstract::Tipranavir is a non-peptidic HIV-1 protease inhibitor. It binds strongly and selectively, has a favourable resistance profile, and is administered orally twice daily with a subtherapeutic dosage of ritonavir in a 'boosted' regimen (TPV/r) in order to increase its bioavailability. Analysis of clinical isolates from tre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565120-00005

    authors: Croom KF,Keam SJ

    更新日期:2005-01-01 00:00:00

  • [Clinical experience with nifedipine in the treatment of angina pectoris in Japan].

    abstract::Developed by Bayer in Germany, nifedipine was shown to be effective in the treatment of patients with angina pectoris by Japanese investigators. Professor Kimura first reported the efficacy of nifedipine in patients with angina pectoris and those findings have been replicated in numerous trials conducted since then. C...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666991-00003

    authors: Hosoda S

    更新日期:2006-01-01 00:00:00

  • Lung tissue penetration of temocillin.

    abstract::Eight patients about to have the whole or part of a lung resected were given a 2g bolus dose of temocillin. A series of serum samples and a piece of peripheral lung tissue were collected and assayed for temocillin concentration. 30 minutes after drug administration, the mean serum and tissue concentrations were 172 mg...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00031

    authors: Cowan W,Baird A,Sleigh JD,Gray JM,Leiper JM,Lawson DH

    更新日期:1985-01-01 00:00:00

  • Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).

    abstract::Interstitial lung disease (ILD) can be associated with all connective tissue diseases and is an important cause of morbidity and mortality. The management of connective tissue disease-interstitial lung disease (CTD-ILD) is challenging due substantial heterogeneity in disease behaviour and paucity of controlled clinica...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01178-x

    authors: Jee AS,Corte TJ

    更新日期:2019-09-01 00:00:00

  • Insulin glulisine: a review of its use in the management of diabetes mellitus.

    abstract::Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. It has similar binding properties, and is associated with a faster onset but similar level of glucose disposal, to regular human insulin (RHI). Insulin gl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969080-00006

    authors: Garnock-Jones KP,Plosker GL

    更新日期:2009-05-29 00:00:00

  • Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia.

    abstract::Pentamidine is an aromatic diamidine derivative which has become one of the standard therapies for Pneumocystis carinii pneumonia (PCP), particularly in patients with acquired immunodeficiency syndrome (AIDS). However, with parenteral administration of the drug there is a high risk of toxicity. Inhaled pentamidine pro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199039050-00008

    authors: Monk JP,Benfield P

    更新日期:1990-05-01 00:00:00

  • Activity of quinolones against mycobacteria.

    abstract::The fluoroquinolones have been shown to be active in vitro against many mycobacterial species, including most strains of Mycobacterium tuberculosis complex and M. fortuitum, and some strains of M. kansasii, M. avium-intracellulare (MAI) complex and M. leprae. Ciprofloxacin, ofloxacin and sparfloxacin are the best stud...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958002-00004

    authors: Jacobs MR

    更新日期:1999-01-01 00:00:00

  • Impact of nifedipine on vascular smooth muscle cell differentiation. Implications for atherogenesis.

    abstract::Although vascular smooth muscle cells (SMCs) play a key role in the development of atherosclerotic lesions, they are not a homogeneous cell type. Myosin has been used as a marker of SMC differentiation in order to identify distinct SMC populations in the adult rabbit aorta. The medial layer of the normal adult aorta c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400481-00003

    authors: Pauletto P,Da Ros S,Zoleo M

    更新日期:1994-01-01 00:00:00

  • Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment.

    abstract::The efficacy of tropisetron in the prevention of nausea and vomiting induced by chemotherapy of varying emetogenic potential was evaluated in 545 patients with a variety of malignancies who had either proved refractory to antiemetic treatment during previous chemotherapy courses or who were considered to be at high ri...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199200433-00007

    authors: Bleiberg H,Van Belle S,Paridaens R,De Wasch G,Dirix LY,Tjean M

    更新日期:1992-01-01 00:00:00

  • Severe asthma: prevention is better than cure.

    abstract::Asthmatic patients during sympton-free periods almost invariably have abnormalities in lung mechanics and gas exchange. Tentacious secretions and mucosal thickening exaggerate maldistribution of ventilation and cause flow limitation in small airways. Hence, the maximal expiratory flow volume loop in these patients wil...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197816030-00007

    authors: Goldstein RS,Slutsky AS,Rebuck AS

    更新日期:1978-09-01 00:00:00

  • Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.

    abstract::The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-alpha -- infliximab, etanercept and adalimumab -- have consistently shown very good efficacy for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868050-00003

    authors: Lutt JR,Deodhar A

    更新日期:2008-01-01 00:00:00

  • Guide to the use of proton pump inhibitors in adult patients.

    abstract::Proton Pump Inhibitors (PPIs) are widely used in the treatment of acid-peptic diseases. Their mechanism of action involves inhibition of the H-K-adenosine triphosphatase enzyme present in the parietal cells of the gastric mucosa. Because PPIs are the most potent inhibitors of gastric acid secretion available, they eff...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868070-00004

    authors: Boparai V,Rajagopalan J,Triadafilopoulos G

    更新日期:2008-01-01 00:00:00

  • The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.

    abstract::The discovery of immune inhibitory checkpoints has revolutionized the approach to the systemic treatment of cancer. The programmed death 1 (PD-1) inhibitory checkpoint, in particular, has played a key role in understanding how certain cancers can evade immune surveillance. Blocking the interaction between the PD-1 rec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0376-z

    authors: Tsai KK,Daud AI

    更新日期:2015-04-01 00:00:00

  • Antiepileptic drug development in children: considerations for a revisited strategy.

    abstract::The European Commission and the European Parliament have acknowledged the specific need for a proper evaluation of new drugs in children. The evaluation of the antiepileptic drugs (AEDs) available on the market illustrates the deficit in therapeutic trials for childhood epilepsy syndromes. Currently, the development o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868010-00002

    authors: Chiron C,Dulac O,Pons G

    更新日期:2008-01-01 00:00:00

  • Azimilide.

    abstract::Azimilide is a potassium channel antagonist that, in contrast to existing class III antiarrhythmic agents, blocks both the rapidly (I(Kr)) and slowly (I(Ks)) activating components of the delayed rectifier potassium current. In animal and clinical studies, azimilide prolonged repolarisation by increasing the action pot...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200059020-00016

    authors: Clemett D,Markham A

    更新日期:2000-02-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Alopecia and hirsuties. Current concepts in pathogenesis and management.

    abstract::Hirsuties and androgenic alopecia are the patterns of hair growth in women which develop in a similar manner to that normally seen in men. This process is mediated by androgens. It may be due to increased hormone production or increased target organ sensitivity. The majority of patients with hirsuties may be adequatel...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835010-00005

    authors: Barth JH

    更新日期:1988-01-01 00:00:00

  • Rilpivirine.

    abstract::Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208590-000000000-00000

    authors: Sanford M

    更新日期:2012-03-05 00:00:00

  • Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

    abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-018-1009-0

    authors: Chen BK,Yang YT,Bennett CL

    更新日期:2018-11-01 00:00:00

  • Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy.

    abstract::Tumour necrosis factor (TNF)-alpha inhibitors are widely used agents in the treatment of a variety of inflammatory and granulomatous diseases. It has long been appreciated that these agents confer an increased risk of tuberculosis; however, more recently it has been recognized that patients being treated with TNFalpha...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969110-00002

    authors: Smith JA,Kauffman CA

    更新日期:2009-07-30 00:00:00

  • Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

    abstract::Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more fre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969060-00004

    authors: Patel M

    更新日期:2009-01-01 00:00:00

  • Influence of fibrinogen on cardiovascular disease.

    abstract::Results from prevalence, case-control, angiographic and echocardiographic investigations incriminate elevated fibrinogen levels as a strong independent risk factor for the occurrence of initial and recurrent cardiovascular events. Average fibrinogen levels are higher in women and persons with other risk factors includ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700543-00006

    authors: Kannel WB

    更新日期:1997-01-01 00:00:00

  • Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.

    abstract::Valsartan/hydrochlorothiazide is a fixed-dose (valsartan 80, 160 or 320mg plus hydrochlorothiazide 12.5 or 25mg) angiotensin II receptor blocker/diuretic drug combination indicated for the treatment of patients with essential hypertension not adequately controlled by monotherapy.There is ample evidence that valsartan/...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/00003495-200666140-00011

    authors: Wagstaff AJ

    更新日期:2006-01-01 00:00:00

  • Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.

    abstract::In a double-blind study, 128 patients with essential hypertension, refractory to beta-blocker monotherapy, were randomised to 1 of 4 treatment groups. Felodipine 2.5 mg twice daily, 5mg twice daily, 10mg twice daily or matched placebo twice daily were administered in addition to the beta-blocker for 4 weeks. Mean supi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700343-00023

    authors: Sluiter HE

    更新日期:1987-01-01 00:00:00

  • Pimavanserin: First Global Approval.

    abstract::Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0597-9

    authors: Markham A

    更新日期:2016-07-01 00:00:00

  • Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

    abstract::The development of chronic heart failure (CHF) includes phenotypic changes in a host of homeostatic systems so that, as the disease advances, CHF may be seen as a multi-system disorder with its origins in the heart but embracing many extra-cardiac manifestations. Immunological abnormalities are recognised in this cont...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060060-00002

    authors: Bolger AP,Anker SD

    更新日期:2000-12-01 00:00:00